Method for preparation of retinal ganglion cells

Patent metadata

Field	Value
Publication number	US-2017191033-A1
Application number	US-201515502321-A
Country	US
Kind code	A1
Filing date	Aug 7, 2015
Priority date	Aug 8, 2014
Publication date	Jul 6, 2017
Grant date	—

Abstract

An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.
The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

First claim

1 . A method for producing retinal ganglion cells with elongated axons, comprising:
(a) inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

2 . The method according to claim 1 , wherein the pluripotent stem cells are induced pluripotent stem cells (iPS cells) or embryonic stem cells (ES cells).

3 . The method according to claim 1 , wherein the adhesion culture is carried out in a medium containing neurotrophic factors.

4 . The method according claim 1 , wherein the adhesion culture is carried out in a medium with a surface level that is the same as the height of the cells.

5 . A culture product of the retinal ganglion cells with elongated axons obtained by a method according to claim 1 .

6 . A cell preparation containing the culture product of retinal ganglion cells according to claim 5 .

7 . A cell sheet containing the culture product of retinal ganglion cells according to claim 5 .

8 . A method for screening a test substance for protective and/or regenerative effects on a retinal nerve, comprising bringing a test substance into contact with the culture product of retinal ganglion cells according to claim 5 and evaluating protective and/or regenerative effects of the test substance on retinal ganglion cells.

9 . A method for treating an eye disease involving retinal ganglion cell damage, comprising administering a therapeutically effective amount of the culture product of retinal ganglion cells according to claim 5 to a mammalian animal in need thereof.

10 .- 11 . (canceled)

Assignees

• Nat Center For Child Health And Dev
• Senju Pharma Co

Inventors

• Azuma Noriyuki
• Tanaka Taku
• Yokoi Tadashi

Classifications

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12N2506/08

  from cells of the nervous system · CPC title

• A61L27/00

  Materials for {grafts or} prostheses or for coating {grafts or} prostheses (dental prostheses A61C13/00; shape or structure of prostheses A61F2/00; use of preparations for artificial teeth A61K6/80; artificial kidneys A61M1/14) · CPC title

• G01N33/5058

  Neurological cells · CPC title